Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals

Report/eBook

Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals

The global market for obesity therapeutics has undergone a seismic shift, what does that mean for strategic GLP-1 dealmaking? Obesity is the hottest sector of the biopharma market, driven by the explosive growth of GLP-1 therapies and the associated dealmaking activity. 2024 alone saw over $30 billion in alliances and acquisitions. In this report, Evaluate’s […]

November 8, 2025

Click to read Obesity and GLP-1 Dealmaking: Strategic Trends and Market Signals

The global market for obesity therapeutics has undergone a seismic shift, what does that mean for strategic GLP-1 dealmaking?

Obesity is the hottest sector of the biopharma market, driven by the explosive growth of GLP-1 therapies and the associated dealmaking activity. 2024 alone saw over $30 billion in alliances and acquisitions.
In this report, Evaluate’s dealmaking experts report on the drivers of GLP-1 dealmaking and investigate trends, barriers, and the role of China as a source of innovation.

Read the report to explore:

Deal trends in obesity including deal stage, key drivers and barriers
Deal volume by modality, targets and RoA
Changes in the treatment landscape as innovation shifts to combination therapies
The investment opportunity as venture dollars continue to pour into the GLP-1 market

Upcoming Webinar

World Preview 2026

Tuesday 16th June 2026 | 3pm BST

By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.

Frequently Asked Questions

What are the key trends shaping dealmaking in the obesity therapeutics market?

The GLP-1 Obesity Deal Trends Report analyzes the latest financial, strategic, and scientific drivers behind alliances, acquisitions, and funding in obesity drug development. It highlights how rising global prevalence, blockbuster GLP-1 sales, and evolving payer dynamics are influencing deal structures and investment priorities.

How is investment activity evolving across development stages in obesity R&D?

The report details how investors and pharma companies are increasingly targeting early-stage assets, with significant funding flowing into discovery, platform, and Phase 2 programs. It also examines the strategic rationale behind late-stage and commercial-stage deals, providing a comprehensive view of the investment landscape.

Why is China emerging as a key player in global obesity drug innovation?

China’s bioscience sector is rapidly advancing, with out-licensing deals and high-quality GLP-1 and amylin analogues attracting global attention. The report explains how Chinese companies are reshaping R&D pipelines and why this matters for multinational pharma and investors seeking new opportunities.

Core Forecasting Products

Regional Forecasts

Forecast Enablement

Bespoke Forecasting

Portfolio & Scenario Analysis

Competitive Context

Pipeline & Asset Intelligence

Deal and Asset Evaluation

Bespoke Business Development Analysis

Scientific & Pipeline Intelligence

Competitive Intelligence Platforms

Epidemiology Context

Market and Company Benchmarks

Custom Solutions

Support

Training and Enablement

Need Help?

Forecasting

Business Development & Licensing

Portfolio Strategy

Competitive Intelligence

Discover Resources

Report/eBook